Equity Overview
Price & Market Data
Price: $22.94
Daily Change: -$1.24 / 5.41%
Daily Range: $22.16 - $24.67
Market Cap: $1,336,176,000
Daily Volume: 1,218,866
Performance Metrics
1 Week: -5.98%
1 Month: -11.42%
3 Months: -12.14%
6 Months: -49.43%
1 Year: -39.35%
YTD: -57.83%
Company Details
Employees: 81
Sector: Health technology
Industry: Biotechnology
Country:
Details
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.